INSM
Price
$159.27
Change
-$4.19 (-2.56%)
Updated
Jan 15 closing price
Capitalization
33.97B
34 days until earnings call
Intraday BUY SELL Signals
INTS
Price
$0.42
Change
-$0.01 (-2.33%)
Updated
Jan 15 closing price
Capitalization
25.11M
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INSM vs INTS

Header iconINSM vs INTS Comparison
Open Charts INSM vs INTSBanner chart's image
Insmed
Price$159.27
Change-$4.19 (-2.56%)
Volume$2.31M
Capitalization33.97B
Intensity Therapeutics
Price$0.42
Change-$0.01 (-2.33%)
Volume$520.91K
Capitalization25.11M
INSM vs INTS Comparison Chart in %
INSM
Daily Signal:
Gain/Loss:
INTS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
INSM vs. INTS commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and INTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (INSM: $159.27 vs. INTS: $0.42)
Brand notoriety: INSM and INTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 70% vs. INTS: 19%
Market capitalization -- INSM: $33.97B vs. INTS: $25.11M
INSM [@Biotechnology] is valued at $33.97B. INTS’s [@Biotechnology] market capitalization is $25.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileINTS’s FA Score has 1 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • INTS’s FA Score: 1 green, 4 red.
According to our system of comparison, both INSM and INTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 5 TA indicator(s) are bullish while INTS’s TA Score has 3 bullish TA indicator(s).

  • INSM’s TA Score: 5 bullish, 4 bearish.
  • INTS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INSM is a better buy in the short-term than INTS.

Price Growth

INSM (@Biotechnology) experienced а -6.46% price change this week, while INTS (@Biotechnology) price change was -3.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +41.99%.

Reported Earning Dates

INSM is expected to report earnings on Feb 19, 2026.

INTS is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($34B) has a higher market cap than INTS($25.1M). INTS YTD gains are higher at: 1.926 vs. INSM (-8.487). INTS has higher annual earnings (EBITDA): -11.72M vs. INSM (-1.09B). INSM has more cash in the bank: 1.68B vs. INTS (7.07M). INTS has less debt than INSM: INTS (118K) vs INSM (576M). INSM has higher revenues than INTS: INSM (447M) vs INTS (0).
INSMINTSINSM / INTS
Capitalization34B25.1M135,458%
EBITDA-1.09B-11.72M9,279%
Gain YTD-8.4871.926-441%
P/E RatioN/AN/A-
Revenue447M0-
Total Cash1.68B7.07M23,772%
Total Debt576M118K488,136%
FUNDAMENTALS RATINGS
INSM: Fundamental Ratings
INSM
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
14
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
33

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INSMINTS
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
63%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
54%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 3 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
72%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signal:
Gain/Loss:
INTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VFQY159.030.93
+0.59%
Vanguard US Quality Factor ETF
WRND38.13N/A
N/A
NYLI Global Equity R&D Leaders ETF
FDCF48.17-0.07
-0.13%
Fidelity Disruptive Communications ETF
XT71.89-0.28
-0.39%
iShares Future Exponential Techs ETF
HOOI10.76-1.64
-13.24%
Defiance Leveraged Long Income Hood ETF

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
-2.56%
THAR - INSM
74%
Closely correlated
-3.27%
ROIV - INSM
40%
Loosely correlated
-2.14%
AXON - INSM
40%
Loosely correlated
+1.27%
ARRY - INSM
40%
Loosely correlated
+6.00%
XENE - INSM
37%
Loosely correlated
-2.02%
More

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and INSM have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and INSM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-1.62%
INSM - INTS
30%
Poorly correlated
-2.56%
ACAD - INTS
28%
Poorly correlated
-1.23%
CCCC - INTS
27%
Poorly correlated
-4.72%
OABI - INTS
25%
Poorly correlated
+0.52%
GPCR - INTS
25%
Poorly correlated
+0.82%
More